Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Guardant Health Inc (NASDAQ: GH) closed the day trading at $54.8 up 1.05% from the previous closing price of $54.23. In other words, the price has increased by $1.05 from its previous closing price. On the day, 2.03 million shares were traded. GH stock price reached its highest trading level at $55.1 during the session, while it also had its lowest trading level at $53.29.
Ratios:
For a better understanding of GH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $55.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
Guggenheim Upgraded its Neutral to Buy on June 28, 2024, while the target price for the stock was maintained at $36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 17 ’25 when Tariq Musa sold 116 shares for $48.20 per share. The transaction valued at 5,591 led to the insider holds 7,324 shares of the business.
POTTER MYRTLE S sold 26 shares of GH for $1,253 on Jul 17 ’25. The Director now owns 18,196 shares after completing the transaction at $48.20 per share. On Jul 17 ’25, another insider, Tariq Musa, who serves as the Director of the company, bought 116 shares for $48.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 6833888768 and an Enterprise Value of 7645225984. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.25. Its current Enterprise Value per Revenue stands at 9.224 whereas that against EBITDA is -18.241.
Stock Price History:
The Beta on a monthly basis for GH is 1.41, which has changed by 0.8426362 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $54.62, while it has fallen to a 52-week low of $20.14. The 50-Day Moving Average of the stock is 14.16%, while the 200-Day Moving Average is calculated to be 33.37%.
Shares Statistics:
Over the past 3-months, GH traded about 2.34M shares per day on average, while over the past 10 days, GH traded about 4199690 shares per day. A total of 124.48M shares are outstanding, with a floating share count of 118.53M. Insiders hold about 4.95% of the company’s shares, while institutions hold 98.85% stake in the company. Shares short for GH as of 1752537600 were 9582594 with a Short Ratio of 4.10, compared to 1749772800 on 9998417. Therefore, it implies a Short% of Shares Outstanding of 9582594 and a Short% of Float of 8.08.
Earnings Estimates
Investors are keenly observing as 14.0 analysts analyze and rate the current performance of Guardant Health Inc (GH) in the stock market.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.4 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.74 and -$1.97 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.63, with 16.0 analysts recommending between -$1.25 and -$2.21.
Revenue Estimates
19 analysts predict $235.66M in revenue for the current quarter. It ranges from a high estimate of $240M to a low estimate of $231.6M. As of the current estimate, Guardant Health Inc’s year-ago sales were $191.48MFor the next quarter, 19 analysts are estimating revenue of $250.43M. There is a high estimate of $254.4M for the next quarter, whereas the lowest estimate is $247.4M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $928.52M, while the lowest revenue estimate was $915.8M, resulting in an average revenue estimate of $921.98M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.12B in the next fiscal year. The high estimate is $1.17B and the low estimate is $1.07B.
